Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
autologous fecal microbiota transplantation (University Hospital, Ghent)
- Development stage
- Unknown
- Lead developer
- Ghent University Hospital
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Gastrointestinal
01
Overview
Autologous fecal microbiota transplantation (FMT) is a microbial therapy being investigated by University Hospital, Ghent, specifically for the decolonization of multi-drug resistant organisms (MDRO), such as Gram-negative bacteria, in hospitalized patients. The procedure involves the administration of a patient's own previously collected and processed fecal microbiota back into their gastrointestinal tract. The therapeutic goal is to restore the patient's native microbial diversity and ecological balance, which may have been disrupted by antibiotic use or illness. By reinstating the original commensal flora, the therapy aims to provide colonization resistance and outcompete resistant bacterial strains that have colonized the gut. In the DEKODON clinical trial, this autologous approach serves as a controlled comparator to allogenic (donor) FMT to determine the efficacy of self-restoration versus donor-driven microbiome replacement.
- Other names
- Autologous FMTAuto-FMTAutologous fecal microbiota transplantation
Beyond the preview
Go deeper on autologous fecal microbiota transplantation (University Hospital, Ghent).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on autologous fecal microbiota transplantation (University Hospital, Ghent).